[144] Clorox Company SEC Filing
Clorox Company (CLX) Form 144 notice reports a proposed sale of 15,041 shares of Common stock through UBS Financial Services on the NYSE with an aggregate market value of $1,861,847.74. The filing shows the shares were acquired and are proposed to be sold on 09/04/2025 following an employee stock option exercise paid in cash. The filer states there have been no securities sold by the account in the past three months and affirms no undisclosed material adverse information is known. The form is a routine Rule 144 notice documenting the intended compliant sale.
Avviso Form 144 di Clorox Company (CLX) segnala la proposta vendita di 15.041 azioni ordinarie tramite UBS Financial Services sul NYSE per un valore complessivo di $1.861.847,74. La comunicazione indica che le azioni sono state acquisite e sono previste in vendita il 04/09/2025, a seguito dell'esercizio di stock option da dipendente pagato in contanti. Il dichiarante precisa che non sono stati venduti titoli dall'account negli ultimi tre mesi e conferma di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate. Il modulo rappresenta una notifica di routine ai sensi della Regola 144 che documenta la vendita conforme prevista.
Aviso Formulario 144 de Clorox Company (CLX) informa de la propuesta de venta de 15.041 acciones ordinarias a trav茅s de UBS Financial Services en la NYSE por un valor total de $1.861.847,74. La presentaci贸n indica que las acciones fueron adquiridas y se propone venderlas el 04/09/2025 tras el ejercicio de opciones sobre acciones por empleado pagado en efectivo. El declarante afirma que no se han vendido valores desde la cuenta en los 煤ltimos tres meses y asegura no tener conocimiento de informaci贸n material adversa no divulgada. El formulario es una notificaci贸n rutinaria conforme a la Regla 144 que documenta la venta prevista y conforme.
韥措鞀� 旎错嵓雼�(CLX) Form 144 韱奠電� NYSE鞐愳劀 UBS Financial Services毳� 韱淀暣 氤错喌欤� 15,041欤茧ゼ 齑濎暋 $1,861,847.74鞐� 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃鞙茧┌ 2025-09-04鞐� 順勱笀鞙茧 歆�旮夒悳 歆侅洂 鞀ろ啞鞓奠厴 頄夓偓 鞚错泟 毵る弰霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 歆�雮� 3臧滌洈臧� 頃措嫻 瓿勳鞐愳劀 歃濌秾鞚� 毵る弰頃� 靷嫟鞚� 鞐嗢溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒電� 鞐嗢潓鞚� 頇曥澑頃╇媹雼�. 鞚� 靹滊電� 攴滌箼 144鞐� 霐半ジ 鞚检儊鞝侅澑 韱奠搿� 鞓堨爼霅� 鞝侂矔頃� 毵る弰毳� 氍胳劀頇旐暅 瓴冹瀰雼堧嫟.
Avis Formulaire 144 de Clorox Company (CLX) signale la vente projet茅e de 15 041 actions ordinaires via UBS Financial Services sur le NYSE pour une valeur globale de 1 861 847,74 $. Le d茅p么t indique que les actions ont 茅t茅 acquises et devraient 锚tre vendues le 04/09/2025 suite 脿 l'exercice d鈥檕ptions d鈥檃chat d鈥檃ctions par un employ茅 pay茅 en esp猫ces. Le d茅clarant pr茅cise qu鈥檃ucun titre n鈥檃 茅t茅 vendu depuis le compte au cours des trois derniers mois et affirme ne pas 锚tre au courant d鈥檌nformations d茅favorables importantes non divulgu茅es. Le formulaire constitue une notification de routine en vertu de la r猫gle 144 documentant la vente pr茅vue et conforme.
Clorox Company (CLX) Form 144-Meldung berichtet 眉ber den geplanten Verkauf von 15.041 Stammaktien 眉ber UBS Financial Services an der NYSE mit einem Gesamtwert von $1.861.847,74. Die Einreichung gibt an, dass die Aktien erworben wurden und am 04.09.2025 zum Verkauf stehen sollen, nach Aus眉bung von Mitarbeiteraktienoptionen, bezahlt in bar. Der Einreicher erkl盲rt, dass in den letzten drei Monaten keine Wertpapiere vom Konto verkauft wurden und best盲tigt, keine nichtoffengelegten wesentlichen nachteiligen Informationen zu kennen. Das Formular ist eine routinem盲脽ige Mitteilung gem盲脽 Regel 144 zur Dokumentation des beabsichtigten regelkonformen Verkaufs.
- Regulatory compliance: The filer disclosed the proposed sale under Rule 144, naming the broker and exchange and providing acquisition details
- Clarity of transaction: The filing specifies the acquisition method (employee stock option exercise), payment method (cash), and identical acquisition and proposed sale date
- None.
Insights
TL;DR: Routine Rule 144 sale disclosed; 15,041 shares worth $1.86M were acquired by option exercise and are being offered through UBS.
The filing documents a standard Rule 144 notice for an insider or other restricted holder following an employee stock option exercise on the same date as the proposed sale. It provides key mechanics: broker (UBS), exchange (NYSE), number of shares (15,041), and aggregate market value ($1,861,847.74). No prior sales in the past three months are reported. The disclosure fulfills regulatory requirements and gives market participants visibility into a near-term potential sale of company stock.
TL;DR: Compliance-focused filing showing adherence to Rule 144 sale-notice obligations after exercise of employee options.
The notice indicates the filer complied with procedural conditions by notifying the market via Form 144 and by representing no undisclosed material adverse information. The transaction is described as an employee stock option exercise with cash payment and immediate proposed sale through a named broker. The document contains no statements about trading plans or 10b5-1 arrangements and reports no other insider sales in the prior three months.
Avviso Form 144 di Clorox Company (CLX) segnala la proposta vendita di 15.041 azioni ordinarie tramite UBS Financial Services sul NYSE per un valore complessivo di $1.861.847,74. La comunicazione indica che le azioni sono state acquisite e sono previste in vendita il 04/09/2025, a seguito dell'esercizio di stock option da dipendente pagato in contanti. Il dichiarante precisa che non sono stati venduti titoli dall'account negli ultimi tre mesi e conferma di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate. Il modulo rappresenta una notifica di routine ai sensi della Regola 144 che documenta la vendita conforme prevista.
Aviso Formulario 144 de Clorox Company (CLX) informa de la propuesta de venta de 15.041 acciones ordinarias a trav茅s de UBS Financial Services en la NYSE por un valor total de $1.861.847,74. La presentaci贸n indica que las acciones fueron adquiridas y se propone venderlas el 04/09/2025 tras el ejercicio de opciones sobre acciones por empleado pagado en efectivo. El declarante afirma que no se han vendido valores desde la cuenta en los 煤ltimos tres meses y asegura no tener conocimiento de informaci贸n material adversa no divulgada. El formulario es una notificaci贸n rutinaria conforme a la Regla 144 que documenta la venta prevista y conforme.
韥措鞀� 旎错嵓雼�(CLX) Form 144 韱奠電� NYSE鞐愳劀 UBS Financial Services毳� 韱淀暣 氤错喌欤� 15,041欤茧ゼ 齑濎暋 $1,861,847.74鞐� 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 旆摑霅橃棃鞙茧┌ 2025-09-04鞐� 順勱笀鞙茧 歆�旮夒悳 歆侅洂 鞀ろ啞鞓奠厴 頄夓偓 鞚错泟 毵る弰霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 歆�雮� 3臧滌洈臧� 頃措嫻 瓿勳鞐愳劀 歃濌秾鞚� 毵る弰頃� 靷嫟鞚� 鞐嗢溂氅�, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒電� 鞐嗢潓鞚� 頇曥澑頃╇媹雼�. 鞚� 靹滊電� 攴滌箼 144鞐� 霐半ジ 鞚检儊鞝侅澑 韱奠搿� 鞓堨爼霅� 鞝侂矔頃� 毵る弰毳� 氍胳劀頇旐暅 瓴冹瀰雼堧嫟.
Avis Formulaire 144 de Clorox Company (CLX) signale la vente projet茅e de 15 041 actions ordinaires via UBS Financial Services sur le NYSE pour une valeur globale de 1 861 847,74 $. Le d茅p么t indique que les actions ont 茅t茅 acquises et devraient 锚tre vendues le 04/09/2025 suite 脿 l'exercice d鈥檕ptions d鈥檃chat d鈥檃ctions par un employ茅 pay茅 en esp猫ces. Le d茅clarant pr茅cise qu鈥檃ucun titre n鈥檃 茅t茅 vendu depuis le compte au cours des trois derniers mois et affirme ne pas 锚tre au courant d鈥檌nformations d茅favorables importantes non divulgu茅es. Le formulaire constitue une notification de routine en vertu de la r猫gle 144 documentant la vente pr茅vue et conforme.
Clorox Company (CLX) Form 144-Meldung berichtet 眉ber den geplanten Verkauf von 15.041 Stammaktien 眉ber UBS Financial Services an der NYSE mit einem Gesamtwert von $1.861.847,74. Die Einreichung gibt an, dass die Aktien erworben wurden und am 04.09.2025 zum Verkauf stehen sollen, nach Aus眉bung von Mitarbeiteraktienoptionen, bezahlt in bar. Der Einreicher erkl盲rt, dass in den letzten drei Monaten keine Wertpapiere vom Konto verkauft wurden und best盲tigt, keine nichtoffengelegten wesentlichen nachteiligen Informationen zu kennen. Das Formular ist eine routinem盲脽ige Mitteilung gem盲脽 Regel 144 zur Dokumentation des beabsichtigten regelkonformen Verkaufs.
FAQ
What does the Form 144 for CLX report?
How were the 15,041 CLX shares acquired?
Does the filing report any sales in the prior three months?
Which broker and exchange are named in the notice?
Does the filer indicate any undisclosed material information about Clorox?
